There is a critical unmet need for safer and more effective treatments for atrial fibrillation (AF), a common cardiac arrhythmia affecting over 59 million people worldwide.
The ElectroPulse PFA System is an Australian-developed medical device that treats atrial fibrillation and flutter. It uses high-voltage electrical pulses delivered through specialised catheters to create precise lesions in the heart. These lesions block abnormal electrical signals that cause arrhythmias.
The system performs pulmonary vein isolation (PVI), posterior wall isolation (PWI), and CTI ablation. A 60-patient Australian study, supported by the TTRA, is part of a global trial of up to 600 patients. Results will support CE Mark, TGA, and FDA approvals.
CathRx will work in close collaboration with leading Australian clinicians and world-renowned research teams. This ensures the technology is developed and validated to the highest clinical standards.
Earlier First-in-Human trials with over 70 patients showed 100% acute success and no device-related serious adverse events. The TTRA project builds on this strong foundation to advance a promising Australian innovation.
TTRA Project: Devices
State: NSW
Project Partners:
Project Lead: Mr Milanjot Singh Assi
TTRA Funding: $1,100,000.00
Co-Contribution: $1,500,000.00 cash; $2,082,026.85 in-kind
Project term: 1 July 2025 – 31 May 2027
